trihexyphenidyl has been researched along with Neuroleptic Malignant Syndrome in 7 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following an evaluation by the psychiatrist, a diagnosis of catatonic schizophrenia was made and he was started on oral sulpiride and benhexol." | 3.79 | Neuroleptic malignant syndrome masked by cerebral malaria. ( Rajesh, KM; Sakthi, AN; Sinnathamby, V, 2013) |
| "Development of neuroleptic malignant syndrome (NMS) following discontinuation of high-dose and high-potency neuroleptic agents is described." | 1.28 | Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. ( Hermesh, H; Munitz, H; Spivak, B; Tyano, S; Weizman, A; Wolovick, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajesh, KM | 1 |
| Sinnathamby, V | 1 |
| Sakthi, AN | 1 |
| Guru, S | 1 |
| Vanamoorthy, U | 1 |
| Loganathan, S | 1 |
| Varghese, M | 1 |
| Irwin, GE | 1 |
| Simon, JE | 1 |
| Spivak, B | 2 |
| Gonen, N | 1 |
| Mester, R | 1 |
| Averbuch, E | 1 |
| Adlersberg, S | 1 |
| Weizman, A | 2 |
| Wang, HC | 1 |
| Hsieh, Y | 1 |
| Wolovick, L | 1 |
| Hermesh, H | 1 |
| Tyano, S | 1 |
| Munitz, H | 1 |
| Lee, TH | 1 |
| Tang, LM | 1 |
7 other studies available for trihexyphenidyl and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Neuroleptic malignant syndrome masked by cerebral malaria.
Topics: Adult; Antipsychotic Agents; Delayed Diagnosis; Fatal Outcome; Humans; Malaria, Cerebral; Malaria, F | 2013 |
Neuroleptic malignant syndrome following abrupt anti-cholinergic withdrawal: a case report.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Female; Humans; Lorazepam; Neuroleptic Malignant Synd | 2014 |
Neuroleptic malignant syndrome.
Topics: Basal Ganglia Diseases; Chronic Disease; Diagnosis, Differential; Dibenzoxazepines; Dose-Response Re | 1984 |
Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Male; Muscarinic Ant | 1996 |
Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy.
Topics: Adult; Apomorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Co | 2001 |
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment.
Topics: Adolescent; Antipsychotic Agents; Chlorpromazine; Dose-Response Relationship, Drug; Drug Therapy, Co | 1990 |
Neuroleptic malignant syndrome.
Topics: Amylases; Haloperidol; Humans; Lipase; Male; Middle Aged; Neuroleptic Malignant Syndrome; Schizophre | 1988 |